αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro

Angiogenesis

Volumn 6, Issue 2, 2003, Pages 105-119

  Nisato, Riccardo E ^a   Tille, Jean Christophe ^a   Jonczyk, Alfred ^b   Goodman, Simon L ^b   Pepper, Michael S ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b MERCK KGAA   (Germany)

Author keywords

Angiogenesis; Extracellular matrix; Integrin

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; CILENGITIDE; COLLAGEN; COLLAGEN TYPE 1; CYCLO(ARGINYL BETA ALANYLASPARTYL DEXTRO PHENYLALANYLVALINE); CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANYLVALINE); CYCLOPEPTIDE; CYTOKINE; EMD 69601; EMD 85189; FIBRIN; FIBRINOGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; INTEGRIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; CYCLO(ARGINYL GLYCYL ASPARTYL PHENYLALANYL VALYL); CYCLO(ARGINYL-GLYCYL-ASPARTYL-PHENYLALANYL-VALYL); PEPTIDE FRAGMENT;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CATTLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL INVASION; CONTROLLED STUDY; DRUG SELECTIVITY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; ANGIOGENESIS; ANIMAL; BIOASSAY; CELL ADHESION; CELL MOTION; CULTURE TECHNIQUE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VASCULAR ENDOTHELIUM;

ANIMALIA; BOS TAURUS; BOVINAE;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL ASSAY; CATTLE; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL MOVEMENT; CLONING, MOLECULAR; COLLAGEN; ENDOTHELIUM, VASCULAR; FIBRIN; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VITRONECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842333243     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000011801.98187.f2     Document Type: Article

References (43)

1. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-32.
2. Byzova TV, Rabbani R, D'Souza SE et al. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost 1998; 80: 726-34.
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
4. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
5. Drake CJ, Cheresh DA, Little CD. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 1995; 108(Pt 7): 2655-61.
6. Clark RA, Tonnesen MG, Gailit J et al. Transient functional expression of alphaVbeta 3 on vascular cells during wound repair. Am J Pathol 1996; 148: 1407-21.
7. Hammes HP, Brownlee M, Jonczyk A et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-33.
8. Basson CT, Kocher O, Basson MD et al. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-beta 1 correlates with reciprocal effects on cell migration. J Cell Physiol 1992; 153: 118-28.
9. Senger DR, Ledbetter SR, Claffey KP et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alpha v beta3 integrin, osteopontin, and thrombin. Am J Pathol 1996; 149: 293-305.
10. Sepp NT, Li LJ, Lee KH et al. Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 1994; 103: 295-9.
11. Friedlander M, Theesfeld CL, Sugita M et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9.
12. Hodivala-Dilke KM, McHugh KP, Tsakiris DA et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-38.
13. Huang X, Griffiths M, Wu J et al. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol 2000; 20: 755-9.
14. Bader BL, Rayburn H, Crowley D et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95: 507-19.
15. Reynolds LE, Wyder L, Lively JC et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8: 27-34.
16. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985; 42: 469-77.
17. Mitjans F, Sander D, Adan J et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108(Pt 8): 2825-38.
18. Kraft S, Diefenbach B, Mehta R et al. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999; 274: 1979-85.
19. Dechantsreiter MA, Planker E, Matha B et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999; 42: 3033-40.
20. Furie MB, Cramer EB, Naprstek BL et al. Cultured endothelial cell monolayers that restrict the transendothelial passage of macromolecules and electrical current. J Cell Biol 1984; 98: 1033-41.
21. Pepper MS, Ferrara N, Orci L et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm 1992; 189: 824-31.
22. Thornton SC, Mueller SN, Levine EM. Human endothelial cells: Use of heparin in cloning and long-term serial cultivation. Science 1983; 222: 623-5.
23. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83: 852-9.
24. Montesano R, Pepper MS, Vassalli JD et al. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. J Cell Physiol 1987; 132: 509-16.
25. Collo G, Pepper MS. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro. J Cell Sci 1999; 112(Pt 4): 569-78.
26. Xu Y, Gurusiddappa S, Rich RL et al. Multiple binding sites in collagen type I for the integrins alpha1beta1 and alpha2beta1. J Biol Chem 2000; 275: 38981-9.
27. Max R, Gerritsen RR, Nooijen PT et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 320-4.
28. Byzova TV, Goldman CK, Pampori N et al. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. Mol Cell 2000; 6: 851-60.
29. Petitclerc E, Stromblad S, von Schalscha TL et al. Integrin alpha(v) beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999; 59: 2724-30.
30. Khwaja A, Rodriguez-Viciana P, Wennstrom S et al. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997; 16: 2783-93.
31. Montesano R, Pepper MS: In vitro assay of endothelial cell invasion and morphogenesis. In Little C, Mironov V, H Sage (eds): Vascular Morphogenesis in Vivo, in Vitro, in Mente. Boston: Birkauser, 1998; 79-110.
32. Cavallaro U, Tenan M, Castelli V et al. Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. J Cell Biochem 2001; 82: 619-33.
33. Xiong JP, Stehle T, Zhang R et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 151-5.
34. Davis GE, Camarillo CW. An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 1996; 224: 39-51.
35. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)-beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000; 156: 1673-83.
36. Gamble JR, Matthias LJ, Meyer G et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993; 121: 931-43.
37. Kraling BM, Wiederschain DG, Boehm T et al. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J Cell Sci 1999; 112(Pt 10): 1599-609.
38. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-21.
39. Folkman J, Tumor angiogenesis. In Bast RC, Kufe DW, Pollock RE et al. (eds) Cancer Medicine. Hamilton, Canada: B.C. Decker, 2000; 132-52.
40. Bell SE, Mavila A, Salazar R et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2001; 114: 2755-73.
41. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-70.
42. Stupack DG, Puente XS, Boutsaboualoy S et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001; 155: 459-70.
43. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nature Med 2002; 8: 193-4.